早洩治療市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類型、劑型、劑型、通路、地區及競爭格局分類，2021-2031年）

全球早洩治療市場預計將從 2025 年的 29.5 億美元成長到 2031 年的 46.4 億美元，複合年成長率為 7.84%。

該市場涵蓋藥物療法，例如選擇性血清素再回收抑制劑（SSRIs）和局部麻醉劑，以及旨在延長射精潛伏期和提高性滿意度的行為療法。推動這一成長的關鍵因素包括全球性功能障礙盛行率的上升，以及圍繞男性健康的污名化現象逐漸減少​​的文化轉變，這鼓勵了更多人尋求醫療諮詢。此外，在現有醫療保健系統中，處方藥和非處方藥的可近性不斷提高，也為該產業的擴張奠定了堅實的基礎。

然而，由於法規環境嚴格，市場面臨許多障礙。許多有效的口服治療藥物缺乏特定核准，尤其是在美國等關鍵地區，迫使患者依賴仿單標示外用藥。這種監管空白阻礙了新產品的商業化，並限制了患者獲得標準化治療方案的機會。根據歐洲泌尿系統協會預測，到2024年，早洩將成為最常見的男性性功能障礙，全球自述盛行率估計在20%至30%之間，凸顯了對核准治療性介入的迫切需求。

市場促進因素

遠端醫療和數位健康平台的普及正在成為全球早洩治療市場的主要驅動力，從根本上改變了患者獲取和使用醫療保健的方式。這些數位化解決方案提供私密的遠端諮詢和直接面對消費者的藥物配送服務，克服了患者難以啟齒的尷尬，避免了傳統泌尿系統就診常常伴隨的恥辱感。這種轉變促使許多以前不願尋求治療的男性更積極參與治療，從而顯著提高了性健康服務的使用率。根據Hims & Hers Health公司於2024年11月發布的“2024年第三季度財務業績報告”，該公司用戶群（主要為個性化性健康產品用戶）已增至200萬，同比成長44%。

同時，創新局部麻醉劑和非處方藥物的引入，透過提供有效且按需的替代方案，重新定義了護理標準，取代了全身性用藥。製造商正致力於開發使用者友善、非侵入性的產品形式，例如擦拭巾、噴霧劑和穿戴式技術，與口服選擇性血清素再回收抑制劑(SSRI) 相比，這些產品副作用較少。 「in2」設備就是這項創新的傑出代表。根據 Virility Medical 公司 2024 年 5 月發布的公告“Virility Medical 推出 in2 設備”，這項非藥物療法的臨床試驗表明，射精控制能力最多可提高 4.7 倍。大型製藥企業的成功案例也印證了該領域的巨大商業性潛力。例如，Recodati 公司報告稱，其泌尿系統和泌尿系統腫瘤科部門在 2024 年實現了 42.6% 的顯著同比成長，這證實了市場對有效男性健康解決方案的需求日益成長。

市場挑戰

嚴格的法規環境是全球早洩治療市場擴張的主要障礙，因為它阻礙了某些療法的順利商業化。在美國等主要市場，由於達泊西汀等標靶治療尚未獲得美國食品藥物管理局(FDA) 的核准，醫療服務提供者不得不依賴處方抗憂鬱症進行仿單標示外治療。這種依賴性給醫生帶來了法律責任風險，並導致報銷政策不一致，從而增加了患者的自付費用，並降低了患者長期堅持治療的動機。這些複雜的監管問題使得獲利前景不明朗，製藥公司也因此不願投資新藥候選藥物的昂貴臨床試驗。

廣泛的患者需求與監管機構為藥物核准制定的嚴格臨床定義之間的脫節，進一步加劇了這項挑戰。根據歐洲泌尿系統的數據，如果採用嚴格的臨床標準，到2024年，早洩的終生盛行率估計約為男性人口的2-3%。這種狹隘的分類限制了認證核可藥的官方市場，與尋求幫助的更廣泛患者群體形成鮮明對比。這最終限制了新型標準化治療方法的獲利能力。

市場趨勢

人們越來越傾向於個人化、多模式的治療方案，從標準化的單一療法轉向個別化客製化的治療計劃，顯著改善了治療效果。與仿單標示外學名藥用藥不同，這些客製化方案通常會結合行為調整和複雜的特定劑量，以最佳化藥物控制並減輕副作用。這一趨勢在領先的數位醫療服務提供者的策略中尤為明顯，他們正致力於研發獨特的雙效配方，以同時針對早洩的生理和心理因素。這種策略轉變帶來了顯著的財務效益。根據 Hims & Hers Health, Inc. 於 2025 年 11 月發布的“2025 年第三季財務業績報告”，其銷售額達到 5.99 億美元，年增 49%。這一顯著成長主要歸功於個人化醫療服務的廣泛應用。

同時，穿戴式神經調節裝置的興起正在開啟一個全新的治療領域，專注於控制射精反射的神經路徑。與僅能麻痺感覺的局部麻醉劑不同，這些非侵入性設備利用經皮電刺激來調節神經活動，為藥物治療無效的患者提供了一種無需藥物的選擇。這項創新同時獲得了監管部門的核准和投資者的支持，標誌著治療領域正朝著高科技、解剖學解決方案的方向發展。正如2025年2月《星論壇報》的報導「明尼蘇達州開發的早洩貼片獲得FDA批准」所報道，Morari Medical公司已成功資金籌措320萬美元用於其創新型神經調節貼片的商業化，這凸顯了市場對基於設備的治療方法的強勁需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球早洩治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（達泊西汀、5型磷酸二酯酶（PDE5）抑制劑、選擇性血清素再回收抑制劑、局部麻醉劑、澤坦）
  • 依類型（口服療法、局部療法）
  • 按劑型（錠劑、噴霧劑）
  • 按通路（醫院、網路藥局、零售藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美早洩治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲早洩治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區早洩治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲早洩治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲早洩治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球早洩治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Premature Ejaculation Treatment Market is projected to expand from USD 2.95 Billion in 2025 to USD 4.64 Billion by 2031, registering a compound annual growth rate of 7.84%. This market encompasses pharmacotherapeutic interventions, such as selective serotonin reuptake inhibitors and topical anesthetics, as well as behavioral therapies aimed at prolonging ejaculation latency and enhancing sexual satisfaction. Key factors propelling this growth include the rising prevalence of sexual dysfunction worldwide and a cultural shift toward reducing the stigma associated with male health, which encourages more individuals to seek medical advice. Furthermore, the growing accessibility of both prescription and over-the-counter treatments across established healthcare systems establishes a solid base for industry expansion.

Nevertheless, the market encounters significant obstacles due to a strict regulatory environment, particularly in major regions like the United States where many effective oral treatments lack specific approval, leading to a reliance on off-label prescribing. This regulatory void creates hurdles for the commercialization of new products and restricts patient access to standardized care pathways. According to the European Association of Urology, in 2024, premature ejaculation was recognized as the most frequent male sexual dysfunction, with self-reported prevalence rates estimated between 20% and 30% globally, highlighting the urgent requirement for approved therapeutic interventions.

Market Driver

The proliferation of telemedicine and digital health platforms acts as a major catalyst for the Global Premature Ejaculation Treatment Market by fundamentally transforming how patients access and engage with care. These digital solutions overcome the significant hurdle of embarrassment by providing discreet, remote consultations and direct-to-consumer medication delivery, thereby circumventing the stigma frequently linked to traditional in-person urology appointments. This shift has engaged a large demographic of men who were previously hesitant to seek treatment, resulting in a marked uptake of sexual health services. According to Hims & Hers Health, Inc., in their 'Third Quarter 2024 Financial Results' from November 2024, the company's subscriber base-which largely utilizes personalized sexual health products-expanded to 2.0 million, signifying a 44% year-over-year increase.

In parallel, the introduction of innovative topical anesthetics and over-the-counter products is redefining treatment standards by offering effective, on-demand alternatives to systemic medications. Manufacturers are increasingly focusing on user-friendly, non-invasive forms such as wipes, sprays, and wearable technology that reduce side effects relative to oral selective serotonin reuptake inhibitors. A notable instance of such innovation is the "in2" device; as stated by Virility Medical in their May 2024 announcement regarding the 'Virility Medical Launches in2 Device', clinical trials for this drug-free option showed up to a 4.7-fold improvement in ejaculation control. The wider commercial potential of this sector is further demonstrated by the success of major pharmaceutical players; for instance, Recordati reported that their urology and uro-oncology division saw a significant 42.6% growth in 2024 compared to the prior year, underscoring the strong and growing demand for effective male health solutions.

Market Challenge

A rigorous regulatory environment poses a major obstacle to the expansion of the Global Premature Ejaculation Treatment Market by hindering the smooth commercialization of specific therapeutic agents. In key markets such as the United States, the absence of Food and Drug Administration approval for targeted treatments like dapoxetine forces healthcare providers to depend on off-label antidepressant prescriptions. This reliance generates liability risks for physicians and leads to inconsistent insurance reimbursement policies, which raises out-of-pocket costs for patients and discourages long-term medical adherence. As a result, pharmaceutical firms are deterred from funding costly clinical trials for new drug candidates, as the route to profitability is obscured by these regulatory complications.

This difficulty is further exacerbated by the gap between widespread patient demand and the stringent clinical definitions mandated by regulatory authorities for drug approval. According to the European Association of Urology, in 2024, the prevalence of the lifelong subtype of premature ejaculation was determined to be roughly 2% to 3% of the male population when subjected to strict clinical criteria. This narrow classification restricts the officially recognized market for approved medications, standing in sharp contrast to the broader population seeking assistance, which ultimately limits the revenue potential for new, standardized therapies.

Market Trends

There is a growing preference for personalized combination therapies, which is significantly enhancing treatment efficacy by moving away from standardized monotherapies toward tailored regimens. Unlike generic off-label prescriptions, these customized solutions frequently integrate pharmacotherapy with behavioral adjustments or compound specific dosages to optimize control while mitigating side effects. This trend is particularly prominent in the strategies of major digital health providers, who are shifting toward proprietary, dual-action formulations that target both the physiological and psychological components of premature ejaculation. This strategic pivot is generating substantial financial outcomes; according to Hims & Hers Health, Inc., in their 'Third Quarter 2025 Financial Results' from November 2025, revenue hit $599 million, representing a 49% year-over-year rise driven largely by the uptake of these personalized health services.

At the same time, the rise of wearable neuromodulation devices is creating a new therapeutic class that focuses on the neural pathways controlling the ejaculatory reflex. Differing from topical anesthetics that merely numb sensation, these non-invasive devices employ transcutaneous electrical stimulation to modulate nerve activity, providing a drug-free option for patients who do not respond to pharmaceutical treatments. This innovation has secured both regulatory validation and investor support, indicating a shift toward high-tech, anatomical solutions. As reported by the Star Tribune in the February 2025 article 'Minnesota-invented patch for premature ejaculation gains FDA clearance', Morari Medical secured $3.2 million to back the commercial release of its innovative neuromodulation patch, highlighting the market's strong demand for device-based interventions.

Key Market Players

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Premature Ejaculation Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Premature Ejaculation Treatment Market, By Drug Type

• Dapoxetine
• Phosphodiesterase Type 5 (PDE5) Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Topical Anesthetics
• Zertane

Premature Ejaculation Treatment Market, By Type

• Oral Therapies
• Topical Therapies

Premature Ejaculation Treatment Market, By Dosage Form

• Pills
• Spray

Premature Ejaculation Treatment Market, By Distribution Channel

• Hospitals
• Online Pharmacies
• Retail Pharmacies

Premature Ejaculation Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Premature Ejaculation Treatment Market.

Available Customizations:

Global Premature Ejaculation Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premature Ejaculation Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, Zertane)
  • 5.2.2. By Type (Oral Therapies, Topical Therapies)
  • 5.2.3. By Dosage Form (Pills, Spray)
  • 5.2.4. By Distribution Channel (Hospitals, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Premature Ejaculation Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Type
  • 6.2.3. By Dosage Form
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Premature Ejaculation Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Premature Ejaculation Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Premature Ejaculation Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Distribution Channel

7. Europe Premature Ejaculation Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Type
  • 7.2.3. By Dosage Form
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Premature Ejaculation Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Premature Ejaculation Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Premature Ejaculation Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Premature Ejaculation Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Premature Ejaculation Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Premature Ejaculation Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Type
  • 8.2.3. By Dosage Form
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Premature Ejaculation Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Premature Ejaculation Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Premature Ejaculation Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Premature Ejaculation Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Premature Ejaculation Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Premature Ejaculation Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Type
  • 9.2.3. By Dosage Form
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Premature Ejaculation Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Premature Ejaculation Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Premature Ejaculation Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Distribution Channel

10. South America Premature Ejaculation Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Type
  • 10.2.3. By Dosage Form
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Premature Ejaculation Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Premature Ejaculation Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Premature Ejaculation Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Premature Ejaculation Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Absorption Pharmaceuticals Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allergan PLC
• 15.3. AstraZeneca PLC
• 15.4. Bayer AG
• 15.5. Eli Lilly and Company
• 15.6. GlaxoSmithKline PLC
• 15.7. Innovus Pharmaceuticals Inc.
• 15.8. Merck & Co., Inc.
• 15.9. Pfizer, Inc.
• 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer